New Tool That Tracks How the Brain Removes Waste Could Offer Clues About Alzheimer’s
discovermagazine - Learn why understanding how the brain clears its waste could help researchers combat neurodegenerative diseases and age-related cognitive decline.
AI Summary: Researchers unveiled an imaging tool that tracks how the brain removes metabolic waste, mapping preferred drainage routes and pinpointing breakdowns associated with Alzheimer’s pathology. The technique could flag early clearance failure years before symptoms, offering potential biomarkers and therapeutic targets—because sometimes the answer to dementia is less about neurons and more about the plumbing.
Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
fiercehealthcare - Oura, the smart ring maker, filed confidentially for an initial public offering after it reached an $11 billion valuation last year.
AI Summary: Ōura has quietly filed confidential paperwork to go public, leveraging surging consumer demand for its smart rings and an aggressive pivot into healthcare data and services. The company is pitching its wearable as a clinical-grade monitoring platform to insurers and providers, aiming to monetize sleep, activity and biometrics while navigating privacy and regulatory scrutiny.
Depressed mice successfully treated with smart contact lenses that zap their brains: New study
medicalxpress - Scientists in South Korea have developed experimental contact lenses designed to send electrical signals through the retina and into brain regions linked to mood. In mice, the technology appeared to improve depression-like behavior.
AI Summary: Preclinical studies report smart contact lenses that deliver tiny electrical signals can reduce depressive-like behaviors in mice, matching effects seen with standard antidepressants. Researchers caution the work is early — promising biologically, but still a long way from fashionable therapeutic eyewear for humans — and will require safety, dosing and translational studies before any clinic-ready hype.
Omid Veiseh: First-in-Human Clinical Trial of IL-2 Cytokine Factories in Refractory Ovarian Cancer
oncodaily - Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn: “Excited to publish the results […]
AI Summary: A first‑in‑human trial of implantable IL‑2 “cytokine factories” in refractory ovarian cancer reported encouraging early safety and biological activity, offering a localized immune‑stimulation strategy that may boost tumor responses while avoiding systemic toxicity. Investigators described the device‑based platform as a potential option for patients with limited alternatives, pending larger efficacy studies.
FDA clears 1st AI sepsis monitoring tool
Giles Bruce / beckershospitalreview - A tool from tech company Bayesian Health has become the first continuous AI sepsis monitor to gain FDA approval. The solution monitors hospital patients to detect deterioration and flag sepsis early on. The application was developed at Baltimore-based Joh…
AI Summary: Regulators have cleared the first AI‑driven sepsis early‑warning system for clinical deployment, enabling hospitals to use algorithmic alerts to identify patients at risk of deterioration earlier. The clearance opens the door for broader adoption of AI in acute care while renewing debates about clinical oversight, false alarms and integration into existing workflows.
500-year-old gold dental bridge is earliest known oral care of its kind in Scotland — and it likely held a fake tooth
livescience - Archaeologists discovered the 20-karat-gold dental wire in the lower jaw of a middle-aged man who lived around 500 years ago in Scotland.
AI Summary: Archaeologists uncovered what appears to be the earliest known gold dental bridge in Scotland, dating roughly four to five centuries ago and likely fitted with a faux tooth. The discovery sheds light on historic dental practice, craftsmanship and status signaling—proof that vanity and dental innovation are nothing new.
1K steps daily after surgery can cut readmissions by 16%: 3 study notes
Mariah Taylor / beckershospitalreview - Each additional 1,000 steps per day a patient walks after surgery is linked to 18% lower odds of complications, 16% lower readmission rates and 6% shorter hospital stays, researchers found. The study, conducted by researchers at Columbus-based Ohio State …
AI Summary: A simple prescription — roughly 1,000 steps per day after surgery — was linked to a 16% reduction in readmissions in recent studies. Researchers suggest wearable step tracking as an inexpensive, scalable recovery aid that encourages mobility, reduces complications, and nudges postoperative care toward behaviourally realistic, low‑tech interventions that actually work.
FDA approves blood test to guide breast cancer therapy
Ella Jeffries / beckershospitalreview - The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas. The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, …
AI Summary: The FDA approved a blood‑based test to help guide breast cancer treatment selection, authorizing a diagnostic that identifies patients more likely to benefit from specific therapies. The move could reduce unnecessary treatments and sharpen precision oncology, though broad clinical adoption will depend on further validation, payer coverage and clinician trust.
- ESMO Breast highlights and expert commentary (4)
- FDA clearances reshape diagnostics and therapies (3)
- Liquid biopsy, mutations and treatment resistance (4)
- All Other Stories
ESMO Breast highlights and expert commentary
FDA clearances reshape diagnostics and therapies
Liquid biopsy, mutations and treatment resistance
All Other Stories
6 Things to Know About Medtronic’s Cyberattack
Katie Adams / medcitynews - Medtronic suffered a cyberattack on its corporate IT systems. The incident highlights growing cybersecurity risks in the medtech sector, with cybergangs increasingly using phishing and other human-engineering tactics to gain access to data.The post 6 Thin…
AI Summary: Medtronic reported an IT systems breach following a cyberattack, prompting an internal probe and operational mitigation efforts. The company is assessing clinical and supply impacts, notifying stakeholders, and coordinating with cybersecurity authorities — a reminder that even medtech giants are not immune to the digital snarls that can ripple through patient care and profits.
Preeclampsia could be treated with 'blood filtering' therapy, early study hints
livescience - A blood-filtering therapy for preeclampsia is safe for pregnant patients and their babies, according to a new pilot study.
AI Summary: Early clinical work suggests removing a circulating anti‑angiogenic factor can safely extend pregnancies in severe preeclampsia. Researchers used targeted extracorporeal filtration to lower soluble Fms‑like tyrosine kinase‑1 (sFlt‑1) levels, improving maternal and fetal stability long enough to delay delivery and reduce immediate risks, meriting larger controlled trials.
Erectile disorder: How science is moving beyond Viagra
medicalxpress - Erectile disorder (ED) refers to a persistent difficulty achieving or maintaining an erection sufficient for satisfying sexual activity. It affects millions of men worldwide, including up to 1 in 4 in the United States. Beyond physical functioning, erecti…
AI Summary: Researchers are advancing alternatives to sildenafil-era approaches for erectile disorder, exploring new biological targets and therapies that aim to restore function rather than just patch symptoms. The coverage explains emerging mechanisms, investigational treatments and the shifting clinical landscape—because sometimes a Band-Aid on performance isn’t the long-term plan.
CMS, FDA announce new program to speed up Medicare coverage of breakthrough medical devices
fiercehealthcare - The Trump administration unveiled a new program to speed up Medicare coverage for breakthrough devices, touting that the new pathway cuts red tape for medical device companies to gain reimbursement. CMS said it will pause the existing TCET pathway.
AI Summary: CMS and the Food and Drug Administration launched a coordinated program to accelerate Medicare coverage for breakthrough medical devices, aiming to shorten the gap between regulatory approval and patient access. The initiative aligns agency review processes, defines eligibility, and seeks faster coverage decisions while maintaining safety and evidentiary standards.
- New imaging and monitoring devices promise faster, remote patient care. (3)
- On scene: agencies align to speed device approvals and coverage. (6)
New imaging and monitoring devices promise faster, remote patient care.
On scene: agencies align to speed device approvals and coverage.
Should you really trust health advice from an AI chatbot?
bbc - Abi has had very mixed results when asking a chatbot for guidance about her health issues.
AI Summary: Recent analyses and a hospital study reveal mainstream AI chatbots frequently provide incorrect or misleading medical guidance and miss initial diagnoses, posing real patient‑safety risks. The research shows these systems can fabricate facts, overconfidently assert dubious recommendations and fail to flag uncertainty, prompting calls for clinician oversight, clearer warnings and tighter evaluation before trusting bots with health decisions.
- Chatbots misdiagnose and confidently give dangerous medical advice (4)
- Companies race to build clinical AI tools and invest heavily (4)
- Other AI healthcare stories: innovation, payers, workflows, mental health trials (12)
- Researchers demand proof and robust evaluation before clinical AI deployment (5)
- Utah pilots bold AI medical programs, sparking safety debates (3)
- All Other Stories
Chatbots misdiagnose and confidently give dangerous medical advice
Companies race to build clinical AI tools and invest heavily
Other AI healthcare stories: innovation, payers, workflows, mental health trials
Researchers demand proof and robust evaluation before clinical AI deployment
Utah pilots bold AI medical programs, sparking safety debates
All Other Stories
Growing liver tissue directly in the body could ease donor organ shortage
medicalxpress - In patients developing end-stage liver disease, the damage has become too severe for the liver's normally extraordinary regenerative capacity to repair or compensate for it. Once this "point of no return" has been reached, the only option is an organ tran…
AI Summary: Scientists report a technique to grow liver tissue directly inside the body as a potential solution to donor organ shortages, demonstrating functional hepatic tissue formation in preclinical or early clinical models. The promising results have been followed by an editorial expression of concern over methodology and data, prompting calls for independent validation before wider clinical use.
UCLA Researchers Develop Low-Cost Blood Test to Detect Multiple Cancers And Other Diseases From a Single Sample
oncodaily - The new method analyzes genome-wide methylation of DNA circulating in the bloodstream to detect liver, lung, ovarian and stomach cancers, as well as several non-cancer conditions. UCLA scientists have developed […]
AI Summary: Researchers at UCLA introduced a low-cost blood test capable of detecting multiple cancers and other diseases from a single sample, promising broader screening reach and earlier detection. If validated at scale, the technology could lower barriers to multi-cancer screening, reshape diagnostic pathways, and offer cheaper, simpler surveillance—assuming the usual caveats about follow-up testing and false positives.
- Frontline: ctDNA and cfDNA - monitoring, screening, and reliability questions (4)
- On location: early-detection debates, AI risk stratification and screening value (4)
- On the ground: UCLA’s inexpensive blood test expands multi-disease detection (4)
- All Other Stories
Frontline: ctDNA and cfDNA - monitoring, screening, and reliability questions
On location: early-detection debates, AI risk stratification and screening value
On the ground: UCLA’s inexpensive blood test expands multi-disease detection
All Other Stories
CMS proposes mandatory hospital-bundled model for joint replacements
Ella Jeffries / beckershospitalreview - CMS is proposing a mandatory, nationwide episode-based payment model for joint replacements that would hold most hospitals responsible for Medicare spending tied to a patient’s surgery and recovery. Beginning Oct. 1, 2027, the model — referred to as CJR-X…
AI Summary: CMS unveiled a plan to make hospitals participate in a mandatory bundled-payment model for joint replacement surgeries, offering a 2.4% payment increase tied to the new program. The proposal would standardize payment and care pathways nationwide, shifting financial and operational risk onto hospitals while aiming to curb costs and improve outcomes.
WHOOP Secures $575M, Reaches $10B Valuation
Marissa Plescia / medcitynews - WHOOP’S Series G round was led by Collaborative Fund and includes participation from 2PointZero Group, Qatar Investment Authority, Cristiano Ronaldo and LeBron James.The post WHOOP Secures $575M, Reaches $10B Valuation appeared first on MedCity News.
AI Summary: Wearable fitness company Whoop closed a $575 million funding round that values the business at roughly $10 billion, attracting strategic partners including Abbott and health systems like Mayo Clinic. The cash infusion underwrites an aggressive hiring spree and product expansion as Whoop doubles down on clinical collaborations and scaling its sensor and analytics platform.
Cencora acquiring EyeSouth Partners' retina business for $1.1B
fiercehealthcare - EyeSouth Partners' retina specialists will join Cencora's Retina Consultants of America, a management services organization that already boasts the country's largest network of retina centers.
AI Summary: Cencora has agreed to acquire EyeSouth Partners’ retina business for roughly $1.1 billion, strengthening its position in specialty ophthalmology services. The deal transfers a network of retinal care assets and aims to integrate retina-focused clinical operations and distribution under Cencora’s broader eye‑care strategy.
A blood test may tailor breast cancer treatment for older women
medicalxpress - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical …
AI Summary: An ultra‑sensitive circulating tumor DNA assay shows promise in tailoring treatment for older breast cancer patients by detecting molecular signals that could guide therapy decisions and avoid unnecessary interventions. The blood test aims to refine risk stratification and personalize care where standard approaches often lack nuance, potentially sparing frail patients from overtreatment.
- EBCC15: Less overtreatment through personalized radiotherapy and surveillance (4)
- Liquid biopsies and sensors advancing cancer detection beyond breast (4)
- Other: biology and global burden stories (3)
- Ultrasensitive ctDNA: tailoring breast cancer care for older patients (5)
- All Other Stories
EBCC15: Less overtreatment through personalized radiotherapy and surveillance
Liquid biopsies and sensors advancing cancer detection beyond breast
Other: biology and global burden stories
Ultrasensitive ctDNA: tailoring breast cancer care for older patients
All Other Stories
A liquid biopsy blood test may improve children's survival of cancer in Africa
medicalxpress - In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam, Tanzania have shown that a minimally invasive liquid biopsy test can diagnose Burkitt l…
AI Summary: A blood‑based liquid biopsy for EBV‑positive Burkitt’s lymphoma shows promise for earlier, less invasive diagnosis in endemic regions, potentially improving pediatric survival where tissue biopsies are scarce. Early data indicate actionable sensitivity and feasibility for low‑resource settings, offering a scalable path to faster treatment.